Celltrion USA expands access to Humira biosimilar at Costco

The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program.

Adalimumab-aaty is a high-concentration (100mg/mL) and citrate-free biosimilar to AbbVie’s (NYSE: ABBV) mega blockbuster drug Humira (adalimumab).

Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and Hidradenitis Suppurativa. The treatment has been available in the USA from Costco Specialty Pharmacy on October 1, 2023 for self-funded employer plans and will now be available for all Costco members through the Costco Member Prescription Program.